Common Contracts

EX-10.23 2 htgm-ex1023_1405.htm EX-10.23 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under

Master Assay Development, Commercialization and Manufacturing Agreement • May 5th, 2020 • Delaware

• Contract Type
  Master Assay Development, Commercialization and Manufacturing Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  Delaware

Master Assay Development, Commercialization and Manufacturing Agreement

Master Assay Development, Commercialization and Manufacturing Agreement • March 23rd, 2017 • HTG Molecular Diagnostics, Inc • Laboratory analytical instruments • Delaware

• Contract Type
  Master Assay Development, Commercialization and Manufacturing Agreement
• Filed
  March 23rd, 2017
• Company
  HTG Molecular Diagnostics, Inc
• Industry
  Laboratory analytical instruments
• Jurisdiction
  Delaware

This Master Assay Development, Commercialization and Manufacturing Agreement (“Agreement”), is entered into and effective as of November 16, 2016 (the “Effective Date”), by and between QIAGEN Manchester Limited, a UK corporation having offices at Skelton House, Lloyd Street North, Manchester, UK (“QIAGEN”), and HTG Molecular Diagnostics, Inc., a Delaware corporation having offices at 3430 E. Global Loop, Tucson, AZ, U.S.A. 85706 (“HTG”). HTG and QIAGEN are herein referred to each as a “Party” and collectively as the “Parties.”